Grants We Funded
Grant applicants for the 2023 cycle requested a total of nearly $4 million dollars. The PSF Study Section Subcommittees of Basic & Translational Research and Clinical Research evaluated nearly 140 grant applications on the following topics:
The PSF awarded research grants totaling over $1 million dollars to support nearly 30 plastic surgery research proposals.
ASPS/PSF leadership is committed to continuing to provide high levels of investigator-initiated research support to ensure that plastic surgeons have the needed research resources to be pioneers and innovators in advancing the practice of medicine.
Research Abstracts
Search The PSF database to have easy access to full-text grant abstracts from past PSF-funded research projects 2003 to present. All abstracts are the work of the Principal Investigators and were retrieved from their PSF grant applications. Several different filters may be applied to locate abstracts specific to a particular focus area or PSF funding mechanism.
Hydrogen sulfide as pre-and post-ischemic cytoprotectant in vivo
Jason Spector MD
2009
Joan & Sanford I. Weill Medical College of Cornell University
Pilot Research Grant
General Reconstructive
Ischemia-reperfusion injury (IRI) is an inevitable complication of many surgical and microsurgical procedures. Previous work in our laboratory has shown that when delivered prior to ischemic insult, hydrogen sulfide (H2S) has a protective effect against IRI both in vitro and in vivo. We propose subsequent studies that will continue our in vivo evaluation, with the iterative advancements being an improved method of drug delivery (intravenous systemic administration) and the implementation of an additional in vivo model involving intestinal IRI. Furthermore, we will explore whether a similar protective effect is observed when H2S is delivered after the ischemic insult has occurred. This question is especially relevant because if the protective effect of H2S is as great when delivered post-ischemia as it is when delivered pre-ischemia, then the potential applications of H2S broaden to include the treatment of all ischemic tissue, not just "prophylaxis" against the unavoidable IRI that occurs during free tissue transfer. Finally, we intend to elucidate the intracellular biochemical pathways that underlie the protective effects of H2S.
Dr. Jason Spector is a nationally recognized clinician, researcher and educator. He holds two patents, and has been an integral part several Cornell University-Weill Cornell Medical College translational research teams. He participates in the NIH and Howard Hughes Medical Institute sponsored Clinical Summer Immersion for Biomedical Engineering Program, mentoring engineering doctoral students. Since 2007, he has been a lecturer at Cornell University's Biomedical Engineering Science and Technology course, "Approaches to Problems in Human Needs." Dr. Spector serves as an Ad-Hoc reviewer for six prestigious medical journals, and has presented at national and international medical meetings. He recently served as Moderator of the Emerging Technologies Section, at the American Surgical Congress in 2011.